Markets

LabCorp Buys Pathology, Inc; Expands in Womens' Health

A generic image of a stock chart
Credit: Shutterstock photo

In its effort to expand in women's health testing business, leading medical laboratory tests and services provider Laboratory Corp. of America HoldingsLH recently agreed to purchase all the operating assets of full-service independent women's health laboratory Pathology, Inc. Financial terms of the deal have been kept under wraps. The transaction is expected to close in the first quarter of 2016, subject to certain customary conditions.

Pathology, Inc.'s forte is in reproductive FDA donor testing and anatomic, molecular and digital pathology services. The impending acquisition includes Pathology, Inc.'s patient service centers, which are used to conduct its medical testing and services business.

According to LabCorp, the company's decision to add Pathology, Inc. to its portfolio is a strategic fit as the latter perfectly complements LabCorp's existing women's health service offerings and supports its mission to provide world class diagnostic solutions. Impressively, the transaction meets LabCorp's financial criteria of being accretive to earnings in the first year and to earn cost of capital by the third year.

Of late, LabCorp has strengthened its foothold in the diagnostics space through both organic and inorganic means. Strategic acquisitions and collaborations with leading companies and academic institutions should help the company provide a wider portfolio of tests. The company continues to increase its scale and competencies in clinical laboratory medicine through acquisitions ranging from routine capabilities to highly esoteric testing.

Apart from its mega $6.1 billion acquisition of Covance, completed in Feb 2015; in recent times, LabCorp has acquired LipoScience - a premier esoteric laboratory focused on personalized diagnostics for cardiovascular and metabolic disorders and Bode Technology Group, Inc. - a provider of specialized forensic DNA analysis, proprietary DNA collection products, and relationship testing. Both the acquisitions are consistent with the company's efforts to strengthen its foothold in the personalized diagnostics testing market for cardiovascular and metabolic disorders as well in the forensics and DNA identification testing market.

With awareness on the rise globally, women's health testing is currently emerging as a rapidly evolving area of medicine. We believe, meaningful acquisitions like that of Pathology, Inc., will allow LabCorp's customers advanced access to high-quality testing, going ahead.

Currently, LabCorp has a Zacks Rank #3 (Hold). Some of the better-ranked med/dental-supply stocks are Align Technology Inc. ALGN , AmerisourceBergen Corporation ABC and DENTSPLY International Inc. XRAY . All the three stocks carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ALIGN TECH INC (ALGN): Free Stock Analysis Report

AMERISOURCEBRGN (ABC): Free Stock Analysis Report

DENTSPLY INTL (XRAY): Free Stock Analysis Report

LABORATORY CP (LH): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ALGN XRAY ABC LH

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More